ZIVO got a penny rag mention yesterday if you hadn't seen it. Doesn't say anything worthwhile.
>>>>>>>>>>>>>>>>>>>>>
Today's Edition
Wednesday April 20th, 2016
Stay ahead of the pack with "The QualityStocks Daily", our summary formatted newsletter
containing stock tips from hundreds of online investment newsletters.
Daily.QualityStocks.net
ZIVO Bioscience, Inc. (ZIVO)
Ceocast News and RedChip reported earlier on ZIVO Bioscience, Inc.(ZIVO), and we also report on the Company, here at the QualityStocks Daily Newsletter.
ZIVO Bioscience, Inc.’s dedication is to the study, development, and commercialization of naturally derived compounds and bioactive molecules created by algal and bacterial hosts. The Company has partnered with the Arizona Center for Algae Technology and Innovation (AzCATI) for its research and development (R&D) development programs.
OTCQB-listed, ZIVO Bioscience is re-inventing its Company as a licensor of internally developed intellectual property (IP), which includes its proprietary algae cultures, in addition to IP secured by way of strategic acquisitions. ZIVO Bioscience is based in Keego Harbor, Michigan. It formerly went by the name Health Enhancement Products, Inc. It changed its corporate name to ZIVO Bioscience, Inc. in November of 2014.
ZIVO Bioscience’s commitment is to the ideal of promoting health through employing naturally occurring bioactive agents. These active ingredients are produced and processed to obtain the highest possible efficacy. To maximize the value and earning power of licenses, the Company engages in ongoing R&D to provide its licensees with the scientific and technical support needed to move into production and distribution.
ZIVO Bioscience’s works to totally harness the beneficial effects of its natural bioactive agents and make them affordable and readily available in a useful and convenient form. Its core IP consists of the algae culture itself, the patented process of producing that culture, and also the bioactive compounds or molecules that can undergo extraction. Additionally, ZIVO’s core IP consists of the application of that culture or extract in supporting health maintenance and longevity.
In 2015, ZIVO Bioscience announced that it opened an assay development lab for its wholly-owned subsidiary, WellMetris LLC, in South Bend, Indiana at the Innovation Center near the Notre Dame University campus. The lab co-locates assay development and instrument engineering to streamline the product development process and concentrate on future development initiatives. In late 2015, ZIVO announced that WellMetris successfully concluded manufacturing runs of assays for its proprietary, patent-pending metabolic testing panel for human application. The manufacturing run completes the full wellness panel with the latest assay formulations.
Yesterday, ZIVO Bioscience said that in the nine months since the last shareholder meeting in late June of 2015, the Company has continued to center almost exclusively on dairy cow applications for its proprietary algal biomass, extracts and any high-value bioactive compounds thereof. This is while developing the business case and production scale-up to cultivate and productize this algal biomass.
ZIVO Bioscience, Inc. (ZIVO), closed Wednesday's trading session at $0.0834, up 15.67%, on 12,025 volume with 5 trades. The average volume for the last 60 days is 53,319 and the stock's 52-week low/high is $0.033/$0.2099.
<<<<<<<<<<<<<<<<<
Amigo Mike
